🔥 Turbo-Stock

American Battery Technology's Nevada recycling facility just hit its first positive gross margin, and the company won an appeal to get a $115M DOE grant reinstated for Phase 1 of its Tonopah Flats lithium refinery — a project whose own PFS shows a $2.57B after-tax NPV (21.8% IRR) against a market cap of roughly $356M today, a 7.2x gap. That's the moonshot math. The offsetting reality: Q3 FY26 alone burned $19.6M from operations against just $7.8M revenue and a $33.8M net loss, funded mostly by ATM share sales, and the company is carrying a sub-12-month cash runway with an active ATM facility still in use. This is a real, calculated ค่าขนม bet on the DOE-backed refinery de-risking faster than the balance sheet runs out — not a clean story.

The setup has improved since the Aug 4 report, which was written in the wreckage of the dilutive $20M offering that cut the stock roughly in half. Since then the FDA completed its standard mid-cycle review of the INO-3107 BLA with no new significant issues raised, scheduled the late-cycle review for Q3, and Inovio confirmed cash funds operations into late Q1 2027 — through a potential launch, not merely to the PDUFA. Commercial prep is underway with Syneos Health engaged, and partner ApolloBio posted positive Phase 3 topline for VGX-3100 in China. The open question is unchanged: the file acceptance letter raised an Accelerated Approval eligibility issue, and the FDA still intends to hold an informal meeting on it before the Oct 30 PDUFA. This remains a single-asset binary at a $63M market cap — sized as ค่าขนม regardless of how the mid-cycle read went.

The European Lithium merger — CRML's largest near-term catalyst — now has both a sharper date and a newly-disclosed real risk. European Lithium shareholders vote at an EGM in LATE AUGUST 2026 (scheme booklet filed with ASIC end of July), with implementation targeted early September if approved — a firmer timeline than the previous 'Sep 2026' estimate. But the scheme requires EuLi to hold a minimum A$330M cash balance, and reporting now pegs EuLi roughly A$36.5-37M (~11%) short of that threshold, plus the vote itself needs a dual majority (simple majority of shareholders present AND 75%+ of value voted) under Australian scheme-of-arrangement law — a real procedural and balance-sheet hurdle CRML must clear before the deal can close. Tanbreez pilot plant Stage 1 remains targeted for this month (footings underway, drill rigs mobilizing), and the Kenya Mrima Hill tender is still in its final round with no award date. The stock has held its Aug 3 sector-driven pop rather than reverting, but the market's demonstrated pattern of selling CRML's own good news (not sector sentiment) makes the late-August EGM a genuine two-sided event.

Ocugen has three catalysts converging in Q3 2026: the rolling BLA filing start for OCU400 (retinitis pigmentosa, Phase 3 enrollment complete), interim OCU410ST data in Stargardt disease, and continued OCU410 geographic-atrophy readouts. At a $427M market cap and $1.23 share price against a Street average target of $11.43 (high $22, post a July 2026 hike from Lucid Capital), the market is pricing in very little of the platform's stated potential. Cash runway extends to 2028 after a May 2026 convertible note raise, removing near-term survival risk, but real dilution overhang remains from that note and outstanding warrants. This name has already re-rated hard on incremental good news before (+75% in 2025, +148% over the trailing year on a run of positive preliminary readouts) — the Q3 2026 cluster is the next test of that pattern, with the real pivotal OCU400 Phase 3 data not landing until Q4 2026/Q1 2027.

Mobilicom's SkyHopper PRO and ICE Electronic Warfare Resistance & Cybersecurity Suite are now essential systems on a Tier-1 U.S. drone manufacturer's (>$5B annual sales) loitering munitions, sold to the Department of War under a $249M, 5-year Program of Record. That's roughly 3.8x today's entire $65M market cap in contracted program value alone. The company is debt-free with $17.7M cash (Mar 31, 2026) and terminated its ATM facility, removing the dilution overhang common at this cap tier. Aug 13, 2026 six-month results are the next real catalyst — confirming whether order-flow (most recently $2.2M in new April 2026 purchase orders) is accelerating toward the program's full value. ค่าขนม position sized 2-5% max — this is a binary bet on defense-budget order-flow, not a stable holding.

Rezolve AI delivered H1 2026 revenue of $127M (~20x YoY) and reaffirmed its $360M FY26 guide on Jul 27, backed by enterprise resale partnerships with Tata Consultancy Services, Zilch, and Microsoft and 1,000+ enterprise customers — but the stock only rose 3.1% on that print, a sign the market isn't fully buying the story yet. The bigger update since the last report: the FY2025 20-F (filed Mar 30, 2026) explicitly states 'substantial doubt about our ability to continue as a going concern for at least one year,' citing an $87.1M working-capital deficit and $104M+ of current debt against $111.1M cash, with management's mitigation plan leaning on cost cuts, debt refinancing, and an active ATM equity program with 'substantial available capacity.' ⚠️ SURVIVAL: this is a real, disclosed liquidity/dilution risk, not a hypothetical — but RZLV stays in the moonshot lane because the growth is independently verified (20x revenue, unanimous 5/6-analyst Buy coverage, $10.75 average target), the going-concern language is common for pre-profitability micro-caps racing toward a stated year-end profitability inflection, and the Oct 7 Q3 print is a genuine binary catalyst for both execution and survival. Size well below a standard moonshot allocation given the disclosure.

Vera already cleared its biggest hurdle: TRUTAKNA (atacicept) won FDA accelerated approval on Jul 7, 2026 for high-risk IgA nephropathy — a real, completed regulatory win, not a pending binary. Today's -7.07% drop is a Q1 EPS miss (-$1.69 vs -$1.37 consensus) tied to early commercial-launch spend, not a change to the underlying regulatory or clinical story — though a CRO leadership transition (William Turner retiring to advisor, Nancy Boman succeeding) adds a mild, unrelated distraction. The real near-term catalyst is unchanged: the FDA-agreed, moved-up ORIGIN Phase 3 eGFR analysis lands Q3 2026, setting up a Q4 sBLA for full (non-accelerated) approval. At $29.95 the 12-month consensus of $81.79 (14 analysts, Strong Buy) implies +173%, and the highest named target ($110) implies +267% — both unchanged in dollar terms from two weeks ago, so the percentage upside has simply grown as the price fell.

Savara's MOLBREEVI has a PDUFA date of Nov 22, 2026 (extended 3 months from Aug 22 after the FDA requested additional information — no safety, efficacy, or manufacturing concerns were cited) to become the first and only approved therapy for autoimmune pulmonary alveolar proteinosis, an ultra-rare lung disease with real unmet need. Cash runway to H2 2027 removes near-term dilution risk, and Street consensus already prices in a meaningful probability of approval (avg target ~$9.20, high $16 vs a $5.69 current price). The binary is real: a clean approval could re-rate this as a first-in-class launch story, while a second delay or CRL — a genuine risk given the review has already slipped once — could cut the stock in half overnight.

Palladyne AI has an exclusive US manufacturing and distribution partnership with Israel Aerospace Industries for 'battle-proven' loitering munitions — Northland specifically flagged this as a potential catalyst for a significant Department of War contract opportunity, and raised its target from $10 to $15 on the news. FY26 revenue guidance of $24-27M implies 357-415% YoY growth from 2025's $5.2M base, with a $17M backlog (most expected to convert over the next 12-18 months) providing real visibility. That said, real upside here has compressed: the 4-analyst average is $11.25 (+111%), and even Northland's raised $15 target is +181% — both fall short of this board's classic 200%+ bar, and Jefferies/Alliance Global have separately cut their targets, reflecting genuine analyst disagreement on execution timing.

Bit Digital's Ethereum-treasury-plus-AI/HPC pivot is still real: the company holds ~158,461 ETH (~$280M) plus a 27.04M-share stake in majority-owned WhiteFiber (WYFI, ~$322M as of Q1) funding an AI/HPC buildout via a $100M (expandable to $150M) Ethereum-backed loan. But the setup has deteriorated since our last look — shares fell from $1.59 to $1.38 after the May 14, 2026 Q1 print sent the stock down -15.3% on a revenue miss (-13.7% QoQ) and a $146.7M net loss driven by ETH mark-to-market. Cash fell to $79.5M (from $118.4M at 2025 year-end), the company itself has flagged less than 12 months of runway, and an effective omnibus shelf registration (filed Oct 31, 2025) sits behind a track record of tapping equity markets twice in the past year — meaning further dilution is a live, near-term risk, not a hypothetical one. We keep BTBT on the list but explicitly flag the survival risk: it's still included because the ETH treasury and WhiteFiber stake are real, verifiable balance-sheet assets and the Aug 13, 2026 Q2 print is a genuine binary catalyst with 4 analysts still seeing $4.13 consensus (+199% from here) — but sizing should reflect a cash-constrained story, not a clean catalyst one.